Image source: Getty Images ASX biotech share Opthea Limited (ASX: OPT) remains frozen at 60 cents apiece following a failed Phase 3 clinical trial. In an update this...
Image source: Getty Images The ASX share market is being hit by a wave of investor selling as the market adjusts to what’s going on with...
Image source: Getty Images Investors looking for exposure to the growing field of respiratory healthcare and sleep apnoea treatment may find themselves comparing two ASX-listed giants:...
Image source: Getty Images The world is experiencing a rough start to April 2025 as investors react to the latest tariff news out of the US....
Image source: Getty Images If you are looking for ASX 200 stocks to buy in April after recent weakness, then it could be worth listening to...
Image source: Getty Images Global equity investors have had an especially painful couple of days. Following Liberation Day, tonight’s US jobs report could be the next major...
Image source: Getty Images It’s been a rough month for many S&P/ASX 200 Index (ASX: XJO) shares. But not all! With investors initially bracing for, and...
Image source: Getty Images It has been another busy week for many of Australia’s top brokers. This has led to the release of a number of...
Image source: Getty Images In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) has followed Wall Street’s lead and dropped deep into the red. At the time...
S&P/ASX 200 Index (ASX: XJO) shares are expected to open lower today as the market ponders the impact of new US tariffs. According to the latest...